Skip to main content
Premium Trial:

Request an Annual Quote

Muenster Study Indicates Astute's NephroCheck Can Help Predict AKI in Cardiac Surgery Patients

Premium

A paper published last week in PLOS One indicates that Astute Medical's NephroCheck test can help predict development of acute kidney failure in patients after undergoing cardiac surgery.

In a study of 50 cardiac surgery patients at the University of Muenster, scientists led by Muenster researcher Alexander Zarbock found that the test could predict progression to AKI with a sensitivity of .92 and a specificity of .81.

NephroCheck assesses AKI risk by measuring insulin-like growth-factor binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases (TIMP-2). Astute began selling the test in Europe in October 2012.

According to Astute, AKI is believed to occur in up to 40 percent of adults who undergo cardiac surgery. However, the company noted, the condition is asymptomatic and difficult to predict using traditional clinical measures.

The study is second published this year on the NephroCheck test, following a prospective, multi-center clinical trial of the test published in February in the American Journal of Respiratory and Critical Care Medicine.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.